Skip to main content

Table 3 Estimated caregiver productivity increase with subcutaneous versus intravenous monoclonal antibodies administration

From: Impact of the subcutaneous formulations of trastuzumab and rituximab on efficiency and resource optimization in Spanish hospitals: H-Excelencia study

  Under current conditions Subcutaneous in all eligible patientsa
Rituximab Trastuzumab Rituximab Trastuzumab
In combination with chemotherapy 19.2% 9.9% 39.4% 22.5%
As maintenance therapy 17.0% 34.7% 22.9% 41.4%
Averageb 21.2% 32.5%
  1. aAssuming a complete conversion to SC formulations according to the approved SmPC (45% of rituximab treatments and 91% of trastuzumab treatments)
  2. bBased on the following assumptions: (1) the first dose of rituximab is administered IV in all patients; (2) 48% of the total number of patients have first-line follicular lymphoma and receive 8 cycles of rituximab in combination with chemotherapy and 12 as maintenance therapy, (3) 14% of the total number of patients have relapsed refractory follicular lymphoma and receive 8 cycles of rituximab in combination with chemotherapy and 8 as maintenance therapy, (4) 38% of the total number of patients have diffuse large B-cell lymphoma and receive 8 cycles of rituximab in combination with chemotherapy; (5) trastuzumab is given as first cycle loading dose in combination with chemotherapy, 7 subsequent cycles in combination with chemotherapy, and 10 cycles in maintenance therapy; a total of 18 cycles/year
  3. SC subcutaneous, SmPC summary of product characteristics